Corticotrophin releasing factor: effects on circulating gut and pancreatic peptides in man.
As a CRF-like peptide has been isolated from human gut, we investigated the effect of synthetic CRF-41 100 micrograms on gut and pancreatic peptides in six normal subjects. There was a significant rise in pancreatic polypeptide compared to a control infusion, but no change in plasma insulin, pancreatic glucagon, gastrin, somatostatin, motilin, neurotensin, gastric inhibitory peptide, or cholecystokinin was seen. In addition, there was no change in circulating met-enkephalin. We conclude that the rise in pancreatic polypeptide seen after CRF administration may suggest a role for a CRF-like peptide in the control of pancreatic function.
D000328:Adult; D002766:Cholecystokinin / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D004744:Enkephalin, Methionine / Q000097:blood; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005755:Gastrins / Q000097:blood; D005934:Glucagon / Q000097:blood; D006728:Hormones / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D008297:Male; D009037:Motilin / Q000097:blood; D009496:Neurotensin / Q000097:blood; D010179:Pancreas / Q000187:drug effects*; D010191:Pancreatic Polypeptide / Q000097:blood*; D013004:Somatostatin / Q000097:blood
D005755:Gastrins; D006728:Hormones; D007328:Insulin; D009496:Neurotensin; D013004:Somatostatin; D009037:Motilin; D004744:Enkephalin, Methionine; D005749:Gastric Inhibitory Polypeptide; D010191:Pancreatic Polypeptide; D005934:Glucagon; D002766:Cholecystokinin; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone